Evaluation of serum Amphiregulin levels in breast cancer patients and cancer-free controls

Esther A. Peterson, Eirini Pectasides, Shabana Shabbeer, Lisa Wiechmann, Joseph A. Sparano, Paraic A. Kenny

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Expression of the Epidermal Growth Factor Receptor ligand, Amphiregulin, has been associated with estrogen receptor positive breast cancer. As Amphiregulin is proteolytically released from the surface of breast cancer cells, we investigated the levels of Amphiregulin in the serum of breast cancer patients and cancer-free women to evaluate its potential utility as a breast cancer biomarker.Findings: Serum Amphiregulin levels were quantified by ELISA from 125 cancer-free women and 114 breast cancer patients. No significant association between serum Amphiregulin levels and breast cancer status was detected at two cut-points evaluated.Conclusions: Measurement of serum Amphiregulin levels lacks the necessary sensitivity and specificity for breast cancer screening in the general population.

Original languageEnglish (US)
Article number25
JournalExperimental Hematology and Oncology
Volume2
Issue number1
DOIs
StatePublished - Sep 8 2013

Fingerprint

Breast Neoplasms
Serum
Neoplasms
Tumor Biomarkers
Amphiregulin
Early Detection of Cancer
Epidermal Growth Factor Receptor
Estrogen Receptors
Enzyme-Linked Immunosorbent Assay
Ligands
Sensitivity and Specificity
Population

Keywords

  • Amphiregulin
  • Breast cancer
  • Epidermal growth factor receptor
  • Serum biomarker

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Evaluation of serum Amphiregulin levels in breast cancer patients and cancer-free controls. / Peterson, Esther A.; Pectasides, Eirini; Shabbeer, Shabana; Wiechmann, Lisa; Sparano, Joseph A.; Kenny, Paraic A.

In: Experimental Hematology and Oncology, Vol. 2, No. 1, 25, 08.09.2013.

Research output: Contribution to journalArticle

Peterson, Esther A. ; Pectasides, Eirini ; Shabbeer, Shabana ; Wiechmann, Lisa ; Sparano, Joseph A. ; Kenny, Paraic A. / Evaluation of serum Amphiregulin levels in breast cancer patients and cancer-free controls. In: Experimental Hematology and Oncology. 2013 ; Vol. 2, No. 1.
@article{d2faad7d54c9466cbede7d3948ed1539,
title = "Evaluation of serum Amphiregulin levels in breast cancer patients and cancer-free controls",
abstract = "Background: Expression of the Epidermal Growth Factor Receptor ligand, Amphiregulin, has been associated with estrogen receptor positive breast cancer. As Amphiregulin is proteolytically released from the surface of breast cancer cells, we investigated the levels of Amphiregulin in the serum of breast cancer patients and cancer-free women to evaluate its potential utility as a breast cancer biomarker.Findings: Serum Amphiregulin levels were quantified by ELISA from 125 cancer-free women and 114 breast cancer patients. No significant association between serum Amphiregulin levels and breast cancer status was detected at two cut-points evaluated.Conclusions: Measurement of serum Amphiregulin levels lacks the necessary sensitivity and specificity for breast cancer screening in the general population.",
keywords = "Amphiregulin, Breast cancer, Epidermal growth factor receptor, Serum biomarker",
author = "Peterson, {Esther A.} and Eirini Pectasides and Shabana Shabbeer and Lisa Wiechmann and Sparano, {Joseph A.} and Kenny, {Paraic A.}",
year = "2013",
month = "9",
day = "8",
doi = "10.1186/2162-3619-2-25",
language = "English (US)",
volume = "2",
journal = "Experimental Hematology and Oncology",
issn = "2162-3619",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Evaluation of serum Amphiregulin levels in breast cancer patients and cancer-free controls

AU - Peterson, Esther A.

AU - Pectasides, Eirini

AU - Shabbeer, Shabana

AU - Wiechmann, Lisa

AU - Sparano, Joseph A.

AU - Kenny, Paraic A.

PY - 2013/9/8

Y1 - 2013/9/8

N2 - Background: Expression of the Epidermal Growth Factor Receptor ligand, Amphiregulin, has been associated with estrogen receptor positive breast cancer. As Amphiregulin is proteolytically released from the surface of breast cancer cells, we investigated the levels of Amphiregulin in the serum of breast cancer patients and cancer-free women to evaluate its potential utility as a breast cancer biomarker.Findings: Serum Amphiregulin levels were quantified by ELISA from 125 cancer-free women and 114 breast cancer patients. No significant association between serum Amphiregulin levels and breast cancer status was detected at two cut-points evaluated.Conclusions: Measurement of serum Amphiregulin levels lacks the necessary sensitivity and specificity for breast cancer screening in the general population.

AB - Background: Expression of the Epidermal Growth Factor Receptor ligand, Amphiregulin, has been associated with estrogen receptor positive breast cancer. As Amphiregulin is proteolytically released from the surface of breast cancer cells, we investigated the levels of Amphiregulin in the serum of breast cancer patients and cancer-free women to evaluate its potential utility as a breast cancer biomarker.Findings: Serum Amphiregulin levels were quantified by ELISA from 125 cancer-free women and 114 breast cancer patients. No significant association between serum Amphiregulin levels and breast cancer status was detected at two cut-points evaluated.Conclusions: Measurement of serum Amphiregulin levels lacks the necessary sensitivity and specificity for breast cancer screening in the general population.

KW - Amphiregulin

KW - Breast cancer

KW - Epidermal growth factor receptor

KW - Serum biomarker

UR - http://www.scopus.com/inward/record.url?scp=84978024376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978024376&partnerID=8YFLogxK

U2 - 10.1186/2162-3619-2-25

DO - 10.1186/2162-3619-2-25

M3 - Article

AN - SCOPUS:84978024376

VL - 2

JO - Experimental Hematology and Oncology

JF - Experimental Hematology and Oncology

SN - 2162-3619

IS - 1

M1 - 25

ER -